FRMM Earnings Date & History
Forum Markets, Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:19 PM ET
Forum Markets, Inc
Biotechnology
- Next earnings date
- Thursday, November 12, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.13
- Revenue estimate
- $5.8M
FRMM earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-0.27 | $-0.73 | -175.3% | $1.4M |
| Thursday, May 14, 2026 | Q1 2026 | $-0.22 | $-0.20 | +10.9% | $2.9M |
| Tuesday, March 31, 2026 | Q4 2025 | — | $-12.14 | — | $2.4M |
What the market is watching in FRMM's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next FRMM earnings date?
- Forum Markets, Inc is scheduled to report on Thursday, November 12, 2026 (Time TBD). Dates can change until the company confirms them.
- Does FRMM report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for FRMM?
- Consensus EPS for the upcoming quarter is $-0.13, on revenue of $5.8M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
FRMM earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.